AlzeCure Pharma is a Swedish pharmaceutical company dedicated to the research and development of innovative treatments for Alzheimer’s disease and related cognitive disorders. The company operates through several research platforms, notably NeuroRestore and Alzstatin. The NeuroRestore platform focuses on developing symptomatic drugs aimed at treating cognitive disorders, with the leading candidate ACD856 currently in clinical development. This platform also explores potential applications for other conditions, including depression and cognitive impairments associated with Parkinson’s disease and traumatic brain injury. Meanwhile, the Alzstatin platform is working on small molecule drugs designed to modify the disease process of Alzheimer’s, with two projects currently in preclinical development.

In addition to its Alzheimer’s-focused initiatives, AlzeCure Pharma has a Painless platform that targets severe pain conditions. This includes the drug candidate ACD440, which is in clinical development and addresses neuropathic pain, a significant area of unmet medical need. The TrkA-NAM project, also within the Painless platform, is in the research phase and aims to treat severe pain associated with disorders like osteoarthritis. AlzeCure’s diversified portfolio of drug candidates not only aims to tackle Alzheimer’s disease but also extends to other cognitive disorders and severe pain conditions, reflecting the company’s commitment to addressing critical healthcare challenges.

Sweden

AlzeCure Pharma is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops new, innovative, and effective drugs with a goal to combat Alzheimer's disease.

AlzeCure Pharma

Company Details